The rising health expenditure on medications, especially chronic medications, accounts for a large share of total health care spending and is a major financial issue. US prescription drug spending as a share of health expenditures was estimated to be between 9.8% and 16.8% by different estimators in 2016 [1]. Over the last decade, there has been a growth in the amounts of chronic medications used by patients with chronic diseases in the United States. When evaluating dispensed prescriptions in different therapy areas in the United States, the most significant growth between 2012 and 2017 is observed in medications prescribed for mental health conditions [2]. Similarly, in Israel, health care–related expenditures are also increasing over time, mainly involving private financing such as private insurance [3]. For example, looking at mental health conditions, the incidence of first prescription of stimulant medication for attention-deficit/hyperactivity disorder (ADHD) is growing among children in Israel year-over-year [4,5].

Understanding medication use among patients with chronic diseases is critical to evaluate health care costs better and allocate funds more effectively. Due to the global lack of data in the literature, and more particularly related to Israel in recent years, there is a need to study these issues, with a specific focus on children [6]. Although children more often have acute, short-term illnesses including upper respiratory tract and ear infections, gastroenteritis, and injury-related complaints, a growing body of literature has identified an increased risk for chronic conditions such as obesity [7], asthma [8], type 1 and type 2 diabetes mellitus [9], and ADHD and other psychiatric conditions [10-12].

One challenge to children and youth health is the wide use of psychobehavioral treatments for disruptive behavior disorders [13-16]. Indeed, there is an increasing trend of prescribing psychotropic medications in the pediatric population [17-19]. These psychobehavioral treatments are psycholeptics and psychoanaleptics, which are classified in the Anatomical Therapeutic Chemical (ATC) classification system as codes N05 and N06, respectively [20]. One of the main indications for prescribing psychotropic medications in children is the psychostimulant treatment for ADHD [4,5,21]. Prescription of psychostimulants has significantly increased in most countries worldwide for both preschool and school-aged children [22,23], as well as in Israel, where up to 10% of children have been prescribed psychostimulants [4,5,21,22].

Studying trends in chronic medication use among children in different age groups and from varying sociodemographic backgrounds and distinguishing selected therapy areas may help decision-makers evaluate the relevant expected medication costs and the specific services related to these areas. This study aims to analyze trends in chronic medication use and identify risk factors for such treatments.

This is a retrospective cohort study. The analysis will be done on data extracted from the Clalit Health Services (Clalit) data warehouse. Clalit, the largest health care management organization in Israel, insures 52% of the Israeli population (approximately 4.6 million members), operates 14 hospitals, and manages over 1300 primary care clinics with a network of pharmacies and dental clinics.

The electronic medical records of approximately 1,500,000 children aged 0-18 years old whom Clalit insured each year between 2010-2019 will be analyzed. It is important to highlight that children are those aged between 0 and 18 years according to the current Israeli regulation and the national medical services provided in Israel and thus the same applies to the “pediatric” databases we have access to for our study.

The Clalit data warehouse stores sociodemographic data (date and country of birth, immigration status, gender, marital status of parents, clinic location–based socioeconomic status, and ethnicity) and medical data. Clinical data are collected from continuous real-time inputs from physicians and health service providers from the community and hospital settings and include medical diagnoses, laboratory data, prescription renewal, medications dispensed, clinic and emergency room visits, and consultation appointments with specialists. All relevant information includes a patient identifier, which allows compiling all data relevant to a specific patient into a single record.

In Israel, like in much of the world, a prescription can be valid for a few months (3-12 generally), but the prescription can only be filled by the pharmacist one month (28-30 days) at a time. If a patient purchases a treatment for one month or less, they cannot be defined as a patient with chronic treatment; rather, chronic medical treatment can be defined as a documented purchased prescription for 60 days or more within a year, denoted as “purchased chronic medication” for that year. This definition is valid for adults but, to our knowledge, no definition exists for children. Thus, we will consider it relevant for our study and use the same definition [24,25]. Therefore, it seems preferable to look at recurrent delivery of medications rather than diagnosis, even though the latter may be available in the Clalit data warehouse. Indeed, it is well known that finding and characterizing diseases can be accomplished by integrating different parameters such as biological tests, clinical diagnoses, and medication prescriptions and purchases [26]. However, as this research aims to highlight the prevalence of chronic medication, the diagnosis itself is less critical than the use of medication over time. Additionally, it is essential to point out that the Israeli health system regulation changed in 2015—only since then have non–mental health professionals been able to get diagnosis and medication prescription information about a patient [27]. Thus, medication purchase is the better option for following chronic medication trends.

The chronic medications will be classified using the ATC code [20]. We will further analyze different classes of medications with specific attention to psychobehavioral treatment if classified by the ATC as N05 (psycholeptics) or N06 (psychoanaleptics).

We will further collect, according to the updated approval of the data extraction and ethics committees, sociodemographic variables (ie, date of birth, gender, immigration status, ethnicity, socioeconomic status, geographical region of residency, health care management organization–specific insurance type) and clinical variables (ie, diagnosed medical conditions such as comorbid diagnoses, health services consumption, and lab test results when relevant) for further analysis.

Ethics approval was granted by the ethical committee of the Soroka Medical Center of Clalit (0011-18-MHC; February 3, 2019).

Children are members of Clalit with at least one of their parents. Clalit members between January 2010 and December 2019 aged 0-18 years during that period will be included in the study. However, individuals who were Clalit members for less than one year between January 2010 and December 2019 will be excluded. Members that joined (not newborns) between January 2010 and December 2019 were included, with their related data from the date they joined if they were members for more than one year. Members that left (for any reason) between January 2010 and December 2019 were included if they were members for more than one year.

Several studies will be conducted based on the data that will be retrieved.

This research protocol deals with understanding trends regarding medications considered psychobehavioral treatments and medications considered nonpsychobehavioral treatments. This will support the identification of risk factors and predictors for chronic medication use among children. This knowledge will help the health care system evaluate the expected medication costs and allocate funds more effectively. The study hypothesis is that there will be a gradual increase in chronic medication use over the years. This trend will be more significant for psychobehavioral treatments.

In Israel, an analysis of chronic medication use among children between 2010 and 2019 can reveal long-term prescription and treatment adherence patterns. Over time, analyzing the response of the patient (their parents or caregivers) population will hopefully help improve the policies for the prescriptions and the follow-up of chronic treatments in children.

Recent chronic medication purchase trends were not extensively studied in the Israeli pediatric population.

Moreover, Clalit insured and provided medical services to approximately 4.7 million patients in 2021 and is the largest health care provider in Israel with one of the world’s largest medical data warehouses. The data available span all treatment providers, including hospitals and emergency units.

Nevertheless, this study is limited to Israel, and the overall ethnic distribution of the Clalit population does not fully reflect the overall Israeli demographic composition. The Clalit members comprise, in comparison with the general Israeli population, a higher proportion of Arabs, a lower proportion of ultra-Orthodox members, and globally a higher proportion of members having a low socioeconomic status [30].